FDA Approved: MONTELUKAST — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for montelukast submitted by BluePoint Laboratories under ANDA 203366. The decision denotes approval of changes rela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma
• Exercise-induced Bronchoconstriction
• Perennial Allergic Rhinitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• Montelukast (Montelukast)

Snippet

SUPPL AP for MONTELUKAST (MONTELUKAST)